FDA grants priority review for Novocure’s PMA application of Optune

  • SHARE
Printer Friendly

May 12, 2015

According to Pharmaceutical Business Review, the U.S. Food and Drug Administration granted priority review for a pre-market applicaiton (PMA) for Novocure's Optune. The PMA seeks approval for tumor treating fields in combination with temozolomide chemotherapy, as a first-line treatment for glioblastoma (GBM).

Read more about this story